Stereotaxis Inc (OTCMKTS:STXS) major shareholder Paul J. Isaac sold 11,448 shares of Stereotaxis stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $4.17, for a total value of $47,738.16. Following the completion of the transaction, the insider now owns 26,000 shares in the company, valued at approximately $108,420. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
OTCMKTS STXS opened at $4.08 on Friday. Stereotaxis Inc has a 1 year low of $1.70 and a 1 year high of $5.82. The business’s 50-day moving average is $4.60 and its 200 day moving average is $4.17.
Stereotaxis (OTCMKTS:STXS) last posted its quarterly earnings data on Tuesday, May 5th. The medical equipment provider reported ($0.03) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03). The business had revenue of $5.76 million for the quarter. Stereotaxis had a negative return on equity of 1,456.01% and a negative net margin of 14.80%.
Several hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. raised its holdings in Stereotaxis by 573.8% in the 1st quarter. Citigroup Inc. now owns 15,181 shares of the medical equipment provider’s stock worth $46,000 after acquiring an additional 12,928 shares during the last quarter. Eidelman Virant Capital purchased a new stake in Stereotaxis during the 2nd quarter valued at $49,000. Schonfeld Strategic Advisors LLC purchased a new stake in Stereotaxis during the 4th quarter valued at $70,000. Cubist Systematic Strategies LLC bought a new stake in shares of Stereotaxis during the 4th quarter valued at $85,000. Finally, Jane Street Group LLC bought a new stake in shares of Stereotaxis during the 1st quarter valued at $85,000. Hedge funds and other institutional investors own 20.75% of the company’s stock.
Several research firms have recently commented on STXS. Lake Street Capital lifted their price objective on Stereotaxis from $5.00 to $9.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Cowen began coverage on Stereotaxis in a report on Sunday, April 19th. They issued an “outperform” rating and a $6.00 price objective on the stock. Finally, Zacks Investment Research upgraded Stereotaxis from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Thursday, June 4th.
Stereotaxis, Inc designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures.
Further Reading: CBOE Russell 2000® Volatility Index
Receive News & Ratings for Stereotaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stereotaxis and related companies with MarketBeat.com's FREE daily email newsletter.